1. Wulf-Johansson, H, Lock Johansson, S, Schlosser, A, et al. Localization of microfibrillar-associated protein 4 (MFAP4) in human tissues: clinical evaluation of serum MFAP4 and its association with various cardiovascular conditions. PLoS One. 2013;8:e82243.
Google Scholar | Crossref2. Pilecki, B, Holm, AT, Schlosser, A, et al. Characterization of microfibrillar-associated protein 4 (MFAP4) as a tropoelastin- and Fibrillin-binding protein involved in elastic fiber formation. J Biol Chem. 2016;291:1103-1114.
Google Scholar | Crossref | Medline3. Toyoshima, T, Ishida, T, Nishi, N, Kobayashi, R, Nakamura, T, Itano, T. Differential gene expression of 36-kDa microfibril-associated glycoprotein (MAGP-36/MFAP4) in rat organs. Cell Tissue Res. 2008;332:271-278.
Google Scholar | Crossref | Medline4. Toyoshima, T, Nishi, N, Kusama, H, Kobayashi, R, Itano, T. 36-kDa microfibril-associated glycoprotein (MAGP-36) is an elastin-binding protein increased in chick aortae during development and growth. Exp Cell Res. 2005;307:224-230.
Google Scholar | Crossref | Medline5. Kasamatsu, S, Hachiya, A, Fujimura, T, et al. Essential role of microfibrillar-associated protein 4 in human cutaneous homeostasis and in its photoprotection. Sci Rep. 2011;1:1-10.
Google Scholar | Crossref | Medline6. Hirano, E, Fujimoto, N, Tajima, S, et al. Expression of 36-kDa microfibril-associated glycoprotein (MAGP-36) in human keratinocytes and its localization in skin. J Dermatol Sci. 2002;28:60-67.
Google Scholar | Crossref | Medline7. Kobayashi, R, Tashima, Y, Masuda, H, et al. Isolation and characterization of a new 36-kDa microfibril-associated glycoprotein from porcine aorta. J Biol Chem. 1989;264:17437-17444.
Google Scholar | Crossref | Medline8. Toyoshima, T, Yamashita, K, Furuichi, H, Shishibori, T, Itano, T, Kobayashi, R. Ultrastructural distribution of 36-kD microfibril-associated glycoprotein (MAGP-36) in human and bovine tissues. J Histochem Cytochem. 1999;47:1049-1056.
Google Scholar | SAGE Journals9. Furuichi, H, Yamashita, K, Okada, M, et al. Identification of tranilast-binding protein as 36-kDa microfibril-associated glycoprotein by drug affinity chromatography, and its localization in human skin. Biochem Biophys Res Commun. 2000;270:1002-1008.
Google Scholar | Crossref | Medline10. Schlosser, A, Thomsen, T, Shipley, JM, et al. Microfibril-associated protein 4 binds to surfactant protein A (SP-A) and colocalizes with SP-A in the extracellular matrix of the lung. Scand J Immunol. 2006;64:104-116.
Google Scholar | Crossref | Medline | ISI11. Molleken, C, Sitek, B, Henkel, C, et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology. 2009;49:1257-1266.
Google Scholar | Crossref | Medline | ISI12. Terkelsen, MK, Bendixen, SM, Hansen, D, et al. Transcriptional dynamics of hepatic sinusoid-associated cells after liver injury. Hepatology. 2020;72:2119-2133.
Google Scholar | Crossref | Medline13. Schlosser, A, Pilecki, B, Hemstra, LE, et al. MFAP4 promotes vascular smooth muscle migration, proliferation and accelerates neointima formation. Arterioscler Thromb Vasc Biol. 2016;36:122-133.
Google Scholar | Crossref | Medline14. Pilecki, B, Schlosser, A, Wulf-Johansson, H, et al. Microfibrillar-associated protein 4 modulates airway smooth muscle cell phenotype in experimental asthma. Thorax. 2015;70:862-872.
Google Scholar | Crossref | Medline15. Pan, Z, Yang, K, Wang, H, et al. MFAP4 deficiency alleviates renal fibrosis through inhibition of NF-κB and TGF-β/Smad signaling pathways. FASEB J. 2020;34:14250-14263.
Google Scholar | Crossref | Medline16. Wang, HB, Yang, J, Shuai, W, et al. Deletion of microfibrillar-associated protein 4 attenuates left ventricular remodeling and dysfunction in heart failure. J Am Heart Assoc. 2020;9:e015307.
Google Scholar | Crossref17. Mölleken, C, Poschmann, G, Bonella, F, et al. MFAP4: a candidate biomarker for hepatic and pulmonary fibrosis? Sarcoidosis Vasc Diffuse Lung Dis. 2016;33:41-50.
Google Scholar | Medline18. Saekmose, SG, Schlosser, A, Holst, R, et al. Enzyme-linked immunosorbent assay characterization of Basal variation and heritability of systemic microfibrillar-associated protein 4. PLoS One. 2013;8:e82383.
Google Scholar | Crossref19. Hemstra, LE, Schlosser, A, Lindholt, JS, Sorensen, GL. Microfibrillar-associated protein 4 variation in symptomatic peripheral artery disease. J Transl Med. 2018;16:159.
Google Scholar | Crossref | Medline20. Lindholt, JS, Madsen, M, Kirketerp-Moller, KL, et al. High plasma microfibrillar-associated protein 4 is associated with reduced surgical repair in abdominal aortic aneurysms. J Vasc Surg. 2020;71:1921-1929.
Google Scholar | Crossref | Medline21. Hoffmann-Petersen, B, Suffolk, R, Petersen, JJH, et al. Microfibrillar-associated protein 4 in serum is associated with asthma in Danish adolescents and young adults. Immun Inflamm Dis. 2019;7:150-159.
Google Scholar | Crossref | Medline22. Johansson, SL, Roberts, NB, Schlosser, A, et al. Microfibrillar-associated protein 4: a potential biomarker of chronic obstructive pulmonary disease. Respir Med. 2014;108:1336-1344.
Google Scholar | Crossref | Medline23. Madsen, BS, Thiele, M, Detlefsen, S, et al. GALAXY consortium. Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar-associated protein 4. Liver Int. 2020;40:1701-1712.
Google Scholar | Crossref | Medline24. Molleken, C, Ahrens, M, Schlosser, A, et al. Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients. Clin Mol Hepatol. 2019;25:42-51.
Google Scholar | Crossref | Medline25. Bracht, T, Molleken, C, Ahrens, M, et al. Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients. J Transl Med. 2016;14:201.
Google Scholar | Crossref | Medline26. Bracht, T, Schweinsberg, V, Trippler, M, et al. Analysis of disease-associated protein expression using quantitative proteomics-fibulin-5 is expressed in association with hepatic fibrosis. J Proteome Res. 2015;14:2278-2286.
Google Scholar | Crossref | Medline27. Hoegh, SV, Sorensen, GL, Tornoe, I, et al. Long-term stability and circadian variation in circulating levels of surfactant protein D. Immunobiology. 2010;215:314-320.
Google Scholar | Crossref | Medline28. Saekmose, SG, Mossner, B, Christensen, PB, et al. Microfibrillar-Associated Protein 4: a potential biomarker for screening for liver fibrosis in a mixed patient cohort. PLoS One. 2015;10:e0140418.
Google Scholar | Crossref | Medline29. Gilmore, IT, Burroughs, A, Murray-Lyon, IM, Williams, R, Jenkins, D, Hopkins, A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut. 1995;36:437-441.
Google Scholar | Crossref | Medline | ISI30. Ratziu, V, Charlotte, F, Heurtier, A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898-1906.
Google Scholar | Crossref | Medline | ISI31. Karsdal, MA, Krarup, H, Sand, JM, et al. Review article: the efficacy of biomarkers in chronic fibroproliferative diseases - early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther. 2014;40:233-249.
Google Scholar | Crossref | Medline32. Rossi, E, Adams, LA, Ching, HL, Bulsara, M, MacQuillan, GC, Jeffrey, GP. High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis. Clin Chem Lab Med. 2013;51:1107-1114.
Google Scholar | Crossref | Medline